Gorica D Maric1, Tatjana D Pekmezovic1, Sarlota T Mesaros2,3, Olivera S Tamas2, Jovana B Ivanovic2, Vanja N Martinovic2, Marko M Andabaka4, Aleksa Lj Jovanovic1, Nikola D Veselinovic2, Darija B Kisic-Tepavcevic1, Jelena S Drulovic5,6. 1. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 2. Department of the CNS Immune-Mediated Disorders, Clinic of Neurology, Clinical Center of Serbia, Belgrade, Serbia. 3. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 4. Institute of Genetics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 5. Department of the CNS Immune-Mediated Disorders, Clinic of Neurology, Clinical Center of Serbia, Belgrade, Serbia. drulovicjelena@gmail.com. 6. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. drulovicjelena@gmail.com.
Abstract
BACKGROUND: Comorbidities occur frequently in persons with multiple sclerosis (MS). The aim of the present study was to determine the prevalence of the most common comorbidities in the population of MS patients in Belgrade, Serbia. MATERIAL AND METHODS: Data on diagnosed and fully documented comorbidities were taken from the Belgrade MS population registry. The list of explored comorbidities included cardiovascular, malignant, and autoimmune diseases; psychiatric disorders; epilepsy; and type 2 diabetes. In the data analysis, crude, age- and gender-specific, and age-adjusted prevalence was calculated. Additionally, comorbidities were analyzed in patients with various MS phenotypes. RESULTS: The most prevalent group of comorbidities were psychiatric (prevalence (Prev) = 20.59%, 95% CI 19.10-22.17) and cardiovascular comorbidities (Prev = 15.23%, 95% CI 13.93-16.63). The most prevalent single comorbidities were depression (Prev = 11.82%, 95% CI 10.64-13.11) and hypertension (Prev = 11.41%, 95% CI 10.25-12.68). Type 2 diabetes was significantly more prevalent in patients with primary progressive MS compared with the patients with relapsing-remitting and secondary progressive MS (p < 0.001). We found statistically significant positive correlation between number of comorbidities and progression index (p < 0.001). Patients treated with disease-modifying therapies (DMTs) had significantly higher risk of developing comorbidity, after treatment initiation, compared with those who were untreated (p = 0.001). CONCLUSIONS: Our study demonstrated high prevalence of comorbidities in persons with MS, with psychiatric and cardiovascular diseases being the most common. Furthermore, our findings confirmed the association of comorbidities with progression of disability and emphasized their role in treatment decision-making in MS.
BACKGROUND: Comorbidities occur frequently in persons with multiple sclerosis (MS). The aim of the present study was to determine the prevalence of the most common comorbidities in the population of MS patients in Belgrade, Serbia. MATERIAL AND METHODS: Data on diagnosed and fully documented comorbidities were taken from the Belgrade MS population registry. The list of explored comorbidities included cardiovascular, malignant, and autoimmune diseases; psychiatric disorders; epilepsy; and type 2 diabetes. In the data analysis, crude, age- and gender-specific, and age-adjusted prevalence was calculated. Additionally, comorbidities were analyzed in patients with various MS phenotypes. RESULTS: The most prevalent group of comorbidities were psychiatric (prevalence (Prev) = 20.59%, 95% CI 19.10-22.17) and cardiovascular comorbidities (Prev = 15.23%, 95% CI 13.93-16.63). The most prevalent single comorbidities were depression (Prev = 11.82%, 95% CI 10.64-13.11) and hypertension (Prev = 11.41%, 95% CI 10.25-12.68). Type 2 diabetes was significantly more prevalent in patients with primary progressive MS compared with the patients with relapsing-remitting and secondary progressive MS (p < 0.001). We found statistically significant positive correlation between number of comorbidities and progression index (p < 0.001). Patients treated with disease-modifying therapies (DMTs) had significantly higher risk of developing comorbidity, after treatment initiation, compared with those who were untreated (p = 0.001). CONCLUSIONS: Our study demonstrated high prevalence of comorbidities in persons with MS, with psychiatric and cardiovascular diseases being the most common. Furthermore, our findings confirmed the association of comorbidities with progression of disability and emphasized their role in treatment decision-making in MS.
Entities:
Keywords:
Comorbidity; MS registry; Multiple sclerosis; Prevalence
Authors: A Glaser; A Stahmann; T Meissner; P Flachenecker; D Horáková; P Zaratin; G Brichetto; M Pugliatti; O Rienhoff; S Vukusic; A C de Giacomoni; M A Battaglia; W Brola; H Butzkueven; R Casey; J Drulovic; K Eichstädt; K Hellwig; P Iaffaldano; E Ioannidou; J Kuhle; K Lycke; M Magyari; T Malbaša; R Middleton; K M Myhr; K Notas; A Orologas; S Otero-Romero; T Pekmezovic; J Sastre-Garriga; P Seeldrayers; M Soilu-Hänninen; L Stawiarz; M Trojano; T Ziemssen; J Hillert; C Thalheim Journal: Mult Scler Relat Disord Date: 2018-10-04 Impact factor: 4.339
Authors: Kyla A McKay; Helen Tremlett; John D Fisk; Tingting Zhang; Scott B Patten; Lorne Kastrukoff; Trudy Campbell; Ruth Ann Marrie Journal: Neurology Date: 2018-03-09 Impact factor: 9.910
Authors: Lindsay I Berrigan; John D Fisk; Scott B Patten; Helen Tremlett; Christina Wolfson; Sharon Warren; Kirsten M Fiest; Kyla A McKay; Ruth Ann Marrie Journal: Neurology Date: 2016-03-09 Impact factor: 9.910
Authors: Kaarina Kowalec; Kyla A McKay; Scott B Patten; John D Fisk; Charity Evans; Helen Tremlett; Ruth Ann Marrie Journal: Neurology Date: 2017-11-08 Impact factor: 9.910
Authors: Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Stella Leung; Nancy Yu Journal: Neurology Date: 2015-05-27 Impact factor: 9.910
Authors: Ruth Ann Marrie; Stephen Reingold; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Gary Cutter; Nadia Reider Journal: Mult Scler Date: 2015-01-12 Impact factor: 6.312
Authors: Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider Journal: Mult Scler Date: 2015-01-26 Impact factor: 6.312
Authors: Ruth Ann Marrie; Aaron Miller; Maria Pia Sormani; Alan Thompson; Emmanuelle Waubant; Maria Trojano; Paul O'Connor; Kirsten Fiest; Nadia Reider; Stephen Reingold; Jeffrey A Cohen Journal: Neurology Date: 2016-02-10 Impact factor: 9.910
Authors: Niklas Frahm; Melanie Peters; Jörg Bätzing; David Ellenberger; Manas K Akmatov; Judith Haas; Paulus S Rommer; Alexander Stahmann; Uwe K Zettl; Jakob Holstiege Journal: Ther Adv Neurol Disord Date: 2021-10-06 Impact factor: 6.570